Get started
AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

ABBV trade ideas

Abbvie Inc. (ABBV): Financial & Competitive AnalysisAbout Abbvie: Abbvie Inc. (NYSE: ABBV) stands as a prominent player in the pharmaceutical industry, known for its diverse product portfolio and strategic market positioning. This analysis delves into AbbVie's financial health, growth projections, and its competitive landscape. Financial Highlights: With a robust revenue of $58.054 billion in 2022 and a consistent increase in gross profit, AbbVie showcases financial strength. The company maintains strong operational cash flows, indicating efficient management. Growth Projections: Over the next three years, AbbVie is expected to see a compounded annual growth rate (CAGR) of approximately 6-8%. This projection is based on the company's ongoing product development and market expansion strategies. Competitive Positioning: Johnson & Johnson (JNJ): A diversified healthcare giant with a broader range of products. Pfizer Inc. (PFE): Known for its innovative drugs and recent success in vaccines. Merck & Co Inc (MRK): Strong in oncology and vaccines. Eli Lilly and Co (LLY): A leader in diabetes and cancer treatments. Conclusion: AbbVie, with its focus on research and development in high-demand therapeutic areas, is well-positioned to compete effectively in the dynamic pharmaceutical industry. The expected growth and strong financials make it an attractive consideration for investors. Disclaimer: This analysis is for informational purposes and should not be considered investment advice. Investors should conduct their own research or consult with a financial advisor before making investment decisions.
NYSE:ABBVLong
by thedailyinvestor
ABBVIE Short term buy signal.ABBV is on a bearish 1D technical outlook (RSI = 39.987, MACD = -1.990, ADX = 42.078) but is quite possibly forming a short term bottom as the 1D RSI rebounded from an oversold level (under 30.00), while the MACD is close to forming a Bullish Cross. Every time those two conditions were fulfilled simultaneously inside the 1 year Channel Down, the price was a buy. Go long and target a similar LH trendline to early 2023 (TP = 153.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:ABBVLong
by InvestingScope
1
ABBV AbbVie Options Ahead of EarningsIf you haven`t bought the dip on ABBV here: Then analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 147usd strike price Calls with an expiration date of 2023-11-17, for a premium of approximately $3.30. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABBVLong
by TopgOptions
1
$ABBV: Huge reward to risk long entryNYSE:ABBV offers a very low risk daily trend signal entry, which can evolve into a weekly mean reversion move towards $153.80 by mid September or sooner. Stop loss area should be a bit below the daily uptrend mode @ 135.35 (where buyers accumulated shares at between June 30th and July 13th), as this level should hold as support and prevent the stock from going much lower if retested. Daily trend only anticipates a roughly 2 week long uptrend, but over time it might form new trend signals indicating continuation. If your original bottom entry at the reversal here is never stopped you could just let this run till mid September and land a huge reward to risk profit. Best of luck! Cheers, Ivan Labrie.
NYSE:ABBVLong
by IvanLabrie
2
ABBVIE Any pull-back is a buy opportunity.AbbVie Inc. (ABBV) is having the strongest 1D candle since October 13 2022, hitting the 1D MA200 (orange trend-line) for the first time in almost three months. The long-term pattern is a Channel Down and this one is the bullish leg to a new Lower High. The 1D RSI has breached into overbought (70.00>) territory so any pull-back is a buy, even on the current levels. Our medium-term target is the 0.786 Fibonacci retracement level (158.50) similar to what happened on the December 09 2022 High. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVLong
by TradingShot
1
ABBV more probable to go down first before reaching ATHThis idea is based on Wyckoff's method for determining price objectives using the Point & Figure count of distribution ranges. We can a distribution ranges following schematic 2 for Wyckoff's distribution. If we take count the ranges separately, this yields a potential reversal zone between 118.50 and 94.50 dollar per share. Personally I am intend to buy if price reached 106.50 (mid point) All other information is on the chart. Good luck, NQDecipher
NYSE:ABBVShort
by NQunlocked